GlassScriptPhysician profile
Quinton Barnes
NPI 1508223850
$2,431.17
in general payments reported to CMS, 2019-2025
16 companies · $88.30 in 2025
The $88.30 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $257 · 2023: $747 · 2024: $1,339 · 2025: $88.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,181.16 | 2021-2024 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $506.84 | 2023-2024 | Descovy |
| Merck Sharp & Dohme LLC | $246.79 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Emd Serono, INC. | $93.92 | 2023-2024 | Serostim |
| Lilly USA, LLC | $90.01 | 2023-2024 | Zepbound, Jardiance, Mounjaro |
| Abbvie INC. | $60.41 | 2023-2024 | |
| Theratechnologies INC. | $52.49 | 2023-2024 | Trogarzo, Egrifta |
| Novo Nordisk INC | $39.05 | 2024 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $32.27 | 2023-2024 | Dexcom G6 Transmitter |
| Janssen Biotech, INC. | $31.29 | 2021-2023 | Symtuza |
| Glaxosmithkline, LLC. | $19.17 | 2023 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $17.23 | 2023 | Rexulti |
| Napo Pharmaceuticals INC | $16.68 | 2024 | Mytesi |
| Astrazeneca Pharmaceuticals LP | $15.66 | 2023 | |
| Verity Pharmaceuticals INC. | $15.18 | 2024 | Tlando |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $13.02 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quinton Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.